Review finds limited evidence for ambroxol in Gaucher and genetic Parkinson disease
Reported biological and neurological changes were inconsistent, and clinical benefits remain uncertain.
Moderate evidenceReviewInterpret with caution
Medical disclaimer: This article summarizes research findings and is for informational purposes only. It is not medical advice.
Editorial illustration — not from the study.
Researchers searched medical databases and a clinical-trial registry through August 19, 2026, with an additional Web of Science search during revision. They included 20 reports of clinical outcomes. Most evidence in Gaucher disease came from small, uncontrolled reports, and some reports may have involved overlapping patients.
For GBA1-related Parkinson disease, the review said conclusions remain provisional. Results from the AMBITIOUS study were available only as a non-peer-reviewed preprint and did not show disease modification. The review also noted limited information about the safety of long-term, high-dose ambroxol use.
The question reviewed
The researchers conducted a PRISMA 2020 systematic review of ambroxol, a compound that can enter the central nervous system and increase glucocerebrosidase activity. They searched PubMed/MEDLINE, Europe PMC, SSRN, ClinicalTrials.gov and, during revision, the Web of Science Core Collection, without restrictions on date, language or publication status. Of 149 records from the original searches, 137 were screened, 41 full texts were assessed and 20 clinical outcome reports were included. The review covered human clinical reports involving Gaucher disease and GBA1-related Parkinson disease; the abstract does not describe separate animal or laboratory studies.
What the review concluded
In Gaucher disease, selected patients were reported to have biochemical and neurological improvements, but the measures used and the functional responses differed across reports. Because the evidence was mainly from small, uncontrolled studies, these findings show reported changes rather than a confirmed effect caused by ambroxol.
For GBA1-related Parkinson disease, the review considered the evidence provisional. The AMBITIOUS results were available only as a non-peer-reviewed preprint and did not show disease modification. The review also found that biomarker changes alone cannot establish clinical effectiveness. No GBA1 genotype or functional assay currently defines a validated indication, according to the review.
Who this is relevant to
The findings may be relevant only to people and disease subgroups similar to those represented in the included clinical reports, but the abstract does not provide enough detail to define those groups precisely. They should not be assumed to apply to every person with Gaucher disease, Parkinson disease or a GBA1 variant. The review does not establish a validated indication, and it does not provide evidence that ambroxol changes disease progression.
The significance
This review summarizes the current human clinical evidence for a drug being investigated in two uncommon disease settings. It indicates that biological measurements and some reported patient changes have been observed, but the available evidence is not consistent or strong enough to establish clinical benefit. The findings are relevant mainly to researchers and clinicians evaluating future studies, rather than to all people with Gaucher disease or Parkinson disease.
Limitations & evidence assessment
The underlying reports were mostly small, uncontrolled and sometimes overlapping, so they cannot reliably separate effects associated with ambroxol from other explanations. Clinical outcomes and definitions varied substantially, and the heterogeneity was too large for a meta-analysis. The long-term safety of chronic high-dose treatment was insufficiently studied. Results for GBA1-related Parkinson disease included a non-peer-reviewed preprint, which has not completed peer review. The abstract provides no detailed participant totals, follow-up durations or study-by-study effect estimates.
Why this evidence level: This was a systematic review, but the available clinical evidence mostly came from small, uncontrolled and sometimes overlapping reports. Differences between studies prevented a meta-analysis, and key Parkinson disease results were available only in a non-peer-reviewed preprint.
Evidence levels are editorial estimates derived from study metadata — they are not clinical appraisals.
This systematic review examined randomized human trials of concurrent chemotherapy and radiation for locally advanced head and neck, cervical, esophageal, and non-small-cell lung cancers. Across the included trials, combined treatment was reported to provide better overall survival than radiation alone, but it also caused more severe short-term side effects. The review did not provide enough information in its abstract to show how many trials or patients were included.
Researchers pooled results from seven human studies comparing multiple-staged with single-stage removal and reconstruction of congenital melanocytic nevi, sometimes called congenital moles. Staged surgery was associated with fewer major wound complications and recurrences, as well as slightly shorter and narrower scars, but the studies did not find a clear difference in cosmetic or overall patient satisfaction.
A cluster-randomized human study in 210 adults with recently detected stage 1 hypertension in Uzbekistan compared salt-sensitivity testing followed by assigned medication choices with conventional management. After 12 weeks, more participants in the testing-guided group reached the study's blood pressure target, although the study was small, short, and conducted in only three primary care centers.
